Williamson Legacy Group LLC Acquires Shares of 58,758 Elanco Animal Health Incorporated $ELAN

Williamson Legacy Group LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, Holdings Channel reports. The fund acquired 58,758 shares of the company’s stock, valued at approximately $1,330,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Elanco Animal Health during the 1st quarter worth $2,065,000. Goldman Sachs Group Inc. raised its holdings in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after acquiring an additional 2,445,872 shares during the period. Empowered Funds LLC raised its holdings in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after acquiring an additional 4,121 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Elanco Animal Health by 4.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after acquiring an additional 76,408 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Elanco Animal Health by 2,006.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after acquiring an additional 295,651 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average cost of $20.09 per share, with a total value of $99,867.39. Following the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. Citigroup lifted their price target on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. JPMorgan Chase & Co. lifted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Leerink Partners raised their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, KeyCorp boosted their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.20.

Elanco Animal Health Stock Up 5.3%

Elanco Animal Health stock opened at $22.88 on Wednesday. Elanco Animal Health Incorporated has a fifty-two week low of $12.90 and a fifty-two week high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The firm has a 50 day moving average price of $23.00 and a 200 day moving average price of $23.28. The company has a market capitalization of $11.43 billion, a PE ratio of -45.76, a price-to-earnings-growth ratio of 2.34 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.